This further suggests that the successful treatment of large prostate tumors with oxaliplatin may require the elimination of these immunosuppressive IgA+ plasma cells that are present in both mouse and human PC, and suggests a rational approach to augmenting beneficial chemotherapy effects on the anti-tumor immune response. Here, CD79A is linked to neoplasm.